Year: 2011
Type: dissertation
Abstract: Diabetes mellitus is a chronic disease characterized by high blood sugar levels with\nserious complications, particularly if it is not adequately treated. It is increasingly\nprevalent and burdensome from both a health and economic standpoint globally,\namounting to hundreds of billions of dollars in expenditure each year [1,2]. Also\nincreasing are the numbers and types of pharmaceutical interventions being introduced to\ntreat this disease. Over the next decade, numerous diabetes compounds currently in\ndevelopment are expected to be commercialized, making it essential for the most robust\nand accurate evidence to be available to healthcare decision-makers [3].\nApproximately 90% of people with diabetes are diagnosed as Type 2 (T2D), most often\nin adulthood [4]. In contrast, Type 1 diabetes (T1D) patients are commonly diagnosed as\njuveniles, but live well into adulthood with effective treatment [4]. Consequently, adult\npatients with diabetes, namely T2D, are responsible for most of the health and economic\nburden of this disease. Therefore, much of the effort to improve outcomes and reduce\ncosts in diabetes concentrates on this population.
Author: D Cobden
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: green
Funder: Johns Hopkins University
OpenAlex ID: W1482560912